Suat SARI, Nisha VALAND, Umakhanth Venkatraman GIRIJA

A hybrid ligand and structure-based virtual screening of NCI compound library identifies potential SAPT1 inhibitors

Secretory aspartate proteases (SAPs) is a key virulence factor of Candida spp. enabling adherence to and invasion of host tissues through breakdown of host proteins related to immunological and structural defenses, making them potential drug targets for drug-resistant mycoses, especially where the available therapies fail. To date, no SAP inhibitors for Candida tropicalis, one of the top five most common species isolated in Candida-related mycoses, has been reported. In this study, we report first-time identification of a set of potential C. tropicalis SAP1 (SAPT1) inhibitors through a hybrid ligand-and structure-based virtual screening of National Cancer Institute (NCI) library compounds. The NCI library was refined by filtering off non-druglike molecules. Referring to a known C. albicans SAP inhibitor, a similarity search was performed for the refined library, in addition to a pharmacophore screen using a model of the ligand-receptor interactions between a peptide substrate and SAPT1 obtained from crystallographic data. The compounds selected from these screens were subject to molecular docking to the SAPT1 active site and the top-scoring ligand-receptor complexes were further included in MM-GBSA calculations to optimize the predicted binding affinities. Finally, the selected 16 compounds, which were confirmed to make key interactions with the catalytic residues, were in silico evaluated and found eligible for certain pharmacokinetic properties. As a future prospect, obtaining these virtual hits and testing them in vitro against SAPT1 could validate the virtual screening process and yield the first smallmolecule inhibitors of SAPT.

PDF

___

[1] Sanglard D. Emerging Threats in Antifungal-Resistant Fungal Pathogens. Front Med (Lausanne). 2016; 3: 11. [CrossRef]
[2] Chen KC, Tang J. Amino acid sequence around the epoxide-reactive residues in pepsin. J Biol Chem. 1972; 247(8): 2566-2574. [CrossRef]
[3] Mandujano-Gonzalez V, Villa-Tanaca L, Anducho-Reyes MA, Mercado-Flores Y. Secreted fungal aspartic proteases: A review. Rev Iberoam Micol. 2016; 33(2): 76-82. [CrossRef]
[4] Pichova I, Pavlickova L, Dostal J, Dolejsi E, Hruskova-Heidingsfeldova O, Weber J, Ruml T, Soucek M. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. Eur J Biochem. 2001; 268(9): 2669-2677. [CrossRef]
[5] Forastiero A, Mesa-Arango AC, Alastruey-Izquierdo A, Alcazar-Fuoli L, Bernal-Martinez L, Pelaez T, Lopez JF, Grimalt JO, Gomez-Lopez A, Cuesta I, Zaragoza O, Mellado E. Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrob Agents Chemother. 2013; 57(10): 4769-4781. [CrossRef]
[6] Buchold C, Hemberger Y, Heindl C, Welker A, Degel B, Pfeuffer T, Staib P, Schneider S, Rosenthal PJ, Gut J, Morschhäuser J, Bringmann G, Schirmeister T. New cis-configured aziridine-2-carboxylates as aspartic acid protease inhibitors. ChemMedChem. 2011; 6(1): 141-152. [CrossRef]
[7] Degel B, Staib P, Rohrer S, Scheiber J, Martina E, Buchold C, Baumann K, Morschhäuser J, Schirmeister T. Cis- Configured aziridines are new pseudo-irreversible dual-mode inhibitors of Candida albicans secreted aspartic protease 2. ChemMedChem. 2008; 3(2): 302-315. [CrossRef]
[8] Korting HC, Schaller M, Eder G, Hamm G, Bohmer U, Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother. 1999; 43(8): 2038-2042. [CrossRef]
[9] Tossi A, Benedetti F, Norbedo S, Skrbec D, Berti F, Romeo D. Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases. Bioorg Med Chem. 2003; 11(22): 4719-4727. [CrossRef]
[10] Calugi C, Trabocchi A, De Bernardis F, Arancia S, Navarra P, Cauda R, Cassone A, Guarna A. Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype. Bioorg Med Chem. 2012; 20(24): 7206-7213. [CrossRef]
[11] Trabocchi A, Mannino C, Machetti F, De Bernardis F, Arancia S, Cauda R, Cassone A, Guarna A. Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds. J Med Chem. 2010; 53(6): 2502-2509. [CrossRef]
[12] Symersky J, Monod M, Foundling SI. High-resolution structure of the extracellular aspartic proteinase from Candida tropicalis yeast. Biochemistry. 1997; 36(42): 12700-12710. [CrossRef]
[13] Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015; 10(5): 449-461. [CrossRef]
[14] Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, Aïd M, Boucher G, Rogers PD, Raymond M, Morschhäuser J. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother. 2011; 55(5): 2212-2223. [CrossRef]
[15] Kruger DM, Evers A. Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors. ChemMedChem. 2010; 5(1): 148-158. [CrossRef]
[16] Sastry GM, Inakollu VS, Sherman W. Boosting virtual screening enrichments with data fusion: coalescing hits from two-dimensional fingerprints, shape, and docking. J Chem Inf Model. 2013; 53(7): 1531-1542. [CrossRef]
[17] Sánchez-Portocarrero J, Pérez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis. 2000; 37(3): 169-179. [CrossRef]
[18] Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, Ross GA, Dahlgren MK, Russell E, Von Bargen CD, Abel R, Friesner RA, Harder ED. OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. J Chem Theory Comput. 2021;17(7):4291–300. [CrossRef]
[19] Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. [CrossRef]
[20] Sastry GM, Dixon SL, Sherman W. Rapid shape-based ligand alignment and virtual screening method based on atom/feature-pair similarities and volume overlap scoring. J Chem Inf Model. 2011; 51(10): 2455-2466. [CrossRef]
[21] Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des. 2006; 20(10-11): 647-671. [CrossRef]
[22] Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013; 27(3): 221-234. [CrossRef]
[23] Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006; 49(21): 6177-6196. [CrossRef]
[24] Jacobson MP, Friesner RA, Xiang Z, Honig B. On the role of the crystal environment in determining protein sidechain conformations. J Mol Biol. 2002; 320(3): 597-608. [CrossRef]